Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
169.7 USD | +0.69% | +5.07% | +9.32% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.32% | 298B | |
+45.55% | 754B | |
+40.95% | 630B | |
-5.65% | 352B | |
+19.84% | 331B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+6.51% | 164B | |
+0.28% | 163B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Deutsche Bank Raises AbbVie's Price Target to $175 Form $170